20
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Letter: Considerations for Performing Emergent Neurointerventional Procedures in a COVID-19 Environment

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor: COVID-19 syndrome, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, most commonly presents with upper respiratory infectious symptoms and may lead to hypoxemic failure, the most common cause of ventilation support. 1-5 There may be a hypercoagulable state during SARS-CoV-2 infections that could lead to an increased vascular thrombotic phenomenon and a potential need for neurointerventional procedures. 6-8 We aim to outline practices to be considered when managing COVID-19 patients requiring neurointerventional care. GENERAL PLANNING Given the number of SARS-CoV-2 infections within the community, patients presenting with neurological emergencies needing immediate interventional therapy will not be able to be tested in time, and thus such patients should be considered as persons under investigation (PUIs) for SARS-CoV-2 viral infection. 4 Care of such patients should be performed with maximal personal protective equipment (PPE), including N95 masks. 9,10 All patients needing emergent neurointerventional procedures should be considered PUIs. Maximal PPE should be employed when performing emergent neurointerventional procedures on COVID-19 or PUI patients. Personnel It is ideal to minimize the number of neurointerventional radiology (NIR) attendings, fellows, nurses, and technologists who are in-house at any one time to minimize personnel exposure to SARS-CoV-2. 11 This is feasible with a general trend towards canceling elective procedures during the pandemic. Members of the NIR team need to be appropriately fitted with the N95 mask and be aware as to how to obtain all appropriate PPE as N95s may be stored in secure environments. Those who have facial hair or cannot tolerate an N95 must be trained to use a powered air purifying respirator (PAPR) or follow alternative institutional protocols. One can reuse the N95 for up to 8 h without an outer cover; however, when a face mask is worn over the N95 to prevent gross contamination, its reuse can be extended. During cases it is imperative that team members within the NIR suite restrict their movement and not enter clean areas until the procedure is completed and they have doffed their PPEs appropriately. This will necessitate that a member of the team be placed in the clean control room to obtain the equipment necessary during the procedure. The number of NIR personnel within the hospital setting should be minimal. All team members must be fitted appropriately with N95 masks. An outer standard surgical mask should be worn over the N95 to prolong the shelf life of the N95. NIR personnel should be divided as such to prevent the movement of NIR suite personnel to clean areas. NIR Suite and Control Room NIR suites are typically positive-pressure areas to minimize outside infectious contaminants and prevent procedure-related infections; however, this also increases the risk of spreading aerosolized respiratory secretions from COVID-19 patients. Reports from Singapore and New York University share the idea of converting COVID-designated NIR suites into negative-pressure areas with high efficiency particulate air (HEPA) filters, thus reducing the risk of contaminating air flow systems and minimizing the exposure of clean areas to infectious particulate matter. While there may be a theoretical risk of increasing surgical site infections (SSIs) in a negative-pressure environment, this may be outweighed by the benefits of minimizing the exposure of clean areas to infectious matter. 12 If a facility has 2 NIR suites, one should become the designated suite for COVID+/PUI patients and the other for documented COVID-19-negative patients. The inventory in the COVID-19-designated suite should remain in closed storage closets at all times, or a barrier such as plastic sheets could be secured to cover the inventory. Infrequently used inventory should be removed from the suite and could be stored in the control room or an adjacent anteroom. In addition, you must determine if the control room attached to the COVID NIR suite can be maintained as a clean environment. This can be done if the pressure of the control room can be changed to be higher than that of the NIR suite. If this can be achieved, then portable material within the NIR suite can be moved to the control room. If the control room cannot be maintained as a clean environment, then it is ideal to move nonessential portable equipment from the control room, as it also may require a terminal clean. All COVID-contaminated areas (NIR suite and possibly the control room) will need terminal cleaning from ceiling to floor, including the lights and air ducts. Designate one NIR suite as COVID NIR and remove all portable equipment that may get contaminated. Predetermine supplies needed for the NIR case and take those to COVID NIR. Keep the clean control room entrance to the COVID NIR room closed at all times during the procedure. Maintain 1 team member in the NIR control room to seek needed supplies. Anteroom An anteroom serves as a gateway from the COVID-designated NIR suite to the halls, preventing infectious particulate matter from reaching the halls. 13 The anteroom is a small area outside of the NIR suite under negative pressure and fitted with a HEPA filter allowing for personnel to remove their PPE and wash hands before entering a clean area. The negative pressure within the anteroom prevents contaminated particulate matter from traveling to other parts of the hospital. Most NIR suites may not have an attached anteroom, thus engineering staff should be contacted to build a portable anteroom for the COVID NIR suite. Build an anteroom attached to the COVID-NIR suite to prevent contamination of adjacent clean areas. PREOPERATIVE, OPERATIVE, AND POSTOPERATIVE BEST PRACTICES Transfer from emergency department (ED) to NIR Room All nonintubated patients being transported should have a face mask in place. For an intubated patient, it is safest to maintain a closed circuit until after the procedure is concluded. If that is not possible, extreme caution must be taken while clamping the tube when transferring from bagging to ventilator, or ideally the patient may remain on a single ventilator from ED until after treatment, when the ventilator can be changed in a negative-pressure setting. All personnel working with COVID-19 patients should have maximal PPE. A face mask should be placed on all nonintubated patients during transport. Endotracheal tubes should be clamped before transferring to ventilator. Intubation and Procedure With most NIR emergencies (subarachnoid hemorrhage, carotid blow out, epistaxis, etc), intubation becomes essential for the protection of the airway; however, with large vessel occlusion (LVO)-related ischemic stroke, there continues to be a lack of guidance for the best practice. If intubation is to be performed, it should ideally be performed in a negative-pressure environment to minimize the contamination of adjacent areas and personnel, and hypotension should be avoided in stroke patients. 14 If intubation must be performed in the NIR suite, then only anesthesia staff donning appropriate PPE should be present within the room, and postintubation a barrier around the patient's face should be applied to contain aerosolization. 15 Before entering the NIR suite, you should wait for a period of time (determined by your engineering team) to minimize aerosolized particulate matter within the NIR environment; however, such delays will not be ideal in cases of LVO-related stroke patients. If a negative-pressure room is available, full recirculation time is typically around 3 min, so staff may re-enter the room within 5 min. Other centers have not changed their anesthesia/intubation paradigms secondary to the COVID status. In these circumstances, patients remain on nasal cannula O2 with a face mask, and there is not a need to extubate, which is the largest producer of aerosolized matter. Thus, performing thrombectomies without intubation allows for the avoidance of intubation and extubation (highest risk of aerosolization), risk of patient continuing to be intubated and requiring ventilator and intensive care unit (ICU) room, and prolonged recovery times. Intubation and extubation lead to maximal aerosolization and contamination. Intubation and extubation should ideally be performed in negative-pressure rooms. NIR personnel should not be present for intubations/extubations. NIR should enter with appropriate PPE once airway is secure and patient face barrier is in place. Extubation and Transfer to Final Destination While it is ideal if resources allow for the transport of an intubated patient into a negative-pressure room to extubate, this may be unlikely given the rise in the COVID patient population requiring critical care services and negative-pressure rooms. Thus, if possible, extubate the patient within the NIR environment under the same conditions as described for intubation. Once the patient is extubated and has stopped coughing, it is ideal to transport to the final destination rather than an intermediary stop within the postanesthesia care unit (PACU). This will minimize contamination during transport and minimize the number of healthcare personnel exposed. For those patients not intubated, extubation is avoided; however, they should also be transported to the final destination with a face mask and without stopping in a PACU environment. Flat-panel detector computed tomography (CT) scanning capabilities of modern angiographic equipment may also reduce the need to transport to postprocedure CT. Extubate with a minimal number of surrounding personnel (must use N95s). Transfer the patient to the final destination rather than an intermediary location (PACU). Terminal clean the COVID NIR suite. CONCLUSION The COVID-19 pandemic is affecting most regions of the United States, necessitating a change in our practice patterns. We have outlined general principles to be taken into consideration as neurointerventional teams look to care for their patients while preventing the exposure of other patients as well as healthcare personnel. Disclosures The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The species Severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2

            The present outbreak of a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19) is the third documented spillover of an animal coronavirus to humans in only two decades that has resulted in a major epidemic. The Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses, which is responsible for developing the classification of viruses and taxon nomenclature of the family Coronaviridae, has assessed the placement of the human pathogen, tentatively named 2019-nCoV, within the Coronaviridae. Based on phylogeny, taxonomy and established practice, the CSG recognizes this virus as forming a sister clade to the prototype human and bat severe acute respiratory syndrome coronaviruses (SARS-CoVs) of the species Severe acute respiratory syndrome-related coronavirus, and designates it as SARS-CoV-2. In order to facilitate communication, the CSG proposes to use the following naming convention for individual isolates: SARS-CoV-2/host/location/isolate/date. While the full spectrum of clinical manifestations associated with SARS-CoV-2 infections in humans remains to be determined, the independent zoonotic transmission of SARS-CoV and SARS-CoV-2 highlights the need for studying viruses at the species level to complement research focused on individual pathogenic viruses of immediate significance. This will improve our understanding of virus–host interactions in an ever-changing environment and enhance our preparedness for future outbreaks.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

              As the number of patients increases, there is a growing understanding of the form of pneumonia sustained by the 2019 novel coronavirus (SARS-CoV-2), which has caused an outbreak in China. Up to now, clinical features and treatment of patients infected with SARS-CoV-2 have been reported in detail. However, the relationship between SARS-CoV-2 and coagulation has been scarcely addressed. Our aim is to investigate the blood coagulation function of patients with SARS-CoV-2 infection. In our study, 94 patients with confirmed SARS-CoV-2 infection were admitted in Renmin Hospital of Wuhan University. We prospectively collect blood coagulation data in these patients and in 40 healthy controls during the same period. Antithrombin values in patients were lower than that in the control group (p < 0.001). The values of D-dimer, fibrin/fibrinogen degradation products (FDP), and fibrinogen (FIB) in all SARS-CoV-2 cases were substantially higher than those in healthy controls. Moreover, D-dimer and FDP values in patients with severe SARS-CoV-2 infection were higher than those in patients with milder forms. Compared with healthy controls, prothrombin time activity (PT-act) was lower in SARS-CoV-2 patients. Thrombin time in critical SARS-CoV-2 patients was also shorter than that in controls. The coagulation function in patients with SARS-CoV-2 is significantly deranged compared with healthy people, but monitoring D-dimer and FDP values may be helpful for the early identification of severe cases.
                Bookmark

                Author and article information

                Journal
                Neurosurgery
                Neurosurgery
                neurosurgery
                Neurosurgery
                Oxford University Press
                0148-396X
                1524-4040
                02 May 2020
                02 May 2020
                : nyaa173
                Affiliations
                [1 ] Department of Neurosurgery and Radiology University of Michigan Ann Arbor, Michigan
                [2 ] TriHealth-Mayfield Brain & Spine Cincinnati, Ohio
                [3 ] Department of Neuroradiology West Virginia University Morgantown, West Virginia
                [4 ] Department of Neurosurgery Baylor College of Medicine Houston, Texas
                [5 ] Department of Neurosurgery Thomas Jefferson University Hospital Philadelphia, Pennsylvania
                [6 ] Department of Neurosurgery Jacobs School of Medicine University at Buffalo Buffalo, New York
                [7 ] Department of Neurosurgery New York University Langone Health New York, New York
                [8 ] Department of Neurological Surgery University of Washington Seattle, Washington
                [9 ] Department of Neurosurgery Drexel University College of Medicine Philadelphia, Pennsylvania
                [10 ] Department of Neurosurgery Semmes Murphy Clinic University of Tennessee Memphis, Tennessee
                [11 ] Department of Neurosurgery Mount Sinai New York, New York
                [12 ] Department of Neurosurgery Geisinger Health System Danville, Pennsylvania
                [13 ] Department of Neurosurgery Lenox Hill Hospital New York, New York
                Article
                nyaa173
                10.1093/neuros/nyaa173
                7197580
                32358606
                76cb5045-6042-41c1-bc6c-88c3d4b61d8a
                Copyright © 2020 by the Congress of Neurological Surgeons

                This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                Page count
                Pages: 4
                Categories
                Correspondence
                AcademicSubjects/MED00930
                Neuros/4
                Custom metadata
                PAP

                Comments

                Comment on this article